Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSAGE: Chemoradiation in Elderly Esophageal Cancer
NCT02735057Phase 2Recruiting
- Sponsor
- CHU de Besançon
- Start
- Apr 2016
- Primary completion
- Nov 2028
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label trial of carboplatin and paclitaxel in esophageal cancer (2 arms), sponsored by CHU de Besançon. Primary endpoint: Maximum Tolerated Dose. Started Apr 2016; status: recruiting.
02
Drugs
carboplatinpaclitaxel
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT02735057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02735057.